Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by fracalacson1987on Feb 06, 2021 4:51pm
178 Views
Post# 32494046

GXU.V Ticket to the moon

GXU.V Ticket to the moonGoviex uranium Madaouela project 

Resource Base 116,720,000 lbs
Niger Carried Interest 10%
Niger Working Interest 10%
Goviex net stake, madaouela 80%
Royalties $50/lb U308
Steady state production 2.69 mlbs/year
Uranium recovery 93.7%
Cash flow multiply 1.4x
Gross cash flow US $ 2,734,166,000
Income taxes 25% US $ 683,541,000
Net cash flow US $ 2,050,624,500
Carried working Interest US $ 410,124,900
Net cash flow US $ 1,640,499,600
Projected market cap US $ 2,296,699,440
Projected Book Value Per Share $3.73 USD $4.76 CAN 
<< Previous
Bullboard Posts
Next >>